|
|
|
|
|
|
|
|
|
|
medscape
"We believe that the effect of the Avastin neutralized the effect of weekly paclitaxel," Dr. Chan told Reuters Health in a telephone interview. "If you look at the subgroup of patients who did not get (bevacizumab), weekly paclitaxel was beneficial. In fact, it had a 38% improvement in our cohort in progressive-free survival."
(abstract) NEJM
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.